|
Jul 31
|
In rumored AbbVie deal, Wall Street sees momentum for psychedelics M&A
|
|
Jul 28
|
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
|
|
Jul 23
|
GH Research Announces Global Pivotal Program Plans and Further Development Updates
|
|
Jul 16
|
Wall Street Analysts Believe GH Research (GHRS) Could Rally 107.25%: Here's is How to Trade
|
|
Jul 9
|
GH Research Responds to FDA Clinical Hold on Depression Treatment GH001 Ahead of Schedule
|
|
Sep 3
|
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
|
|
Sep 3
|
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
|
|
May 13
|
Recent Price Trend in GH Research (GHRS) is Your Friend, Here's Why
|
|
May 10
|
Wall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should Know
|
|
May 3
|
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
|
|
Mar 5
|
How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%
|
|
Jan 16
|
Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect?
|
|
Dec 29
|
11 Best Psychedelic Stocks to Buy in 2024
|
|
Dec 20
|
11 Most Promising Psychedelic Stocks According to Hedge Funds
|
|
Dec 19
|
15 Best Falling Stocks To Buy Now
|
|
Aug 23
|
GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates
|